



Alberta Society of  
Gastroenterology

ALBERTA  
DIGESTIVE  
DISEASE  
SUMMIT



C O N F E R E N C E   P R O G R A M

JUNE 14-16, 2013  
CHATEAU LAKE LOUISE  
LAKE LOUISE, ALBERTA

## Organizing Committee

Dr. Robert Bailey, University of Alberta  
Dr. Paul Beck, University of Calgary  
Dr. Kelly Burak, University of Calgary  
Dr. Tara Chalmers-Nixon, University of Calgary  
Dr. Shane Devlin, University of Calgary  
Dr. Richard Fedorak, University of Alberta  
Dr. Mani Kareemi, University of Calgary  
Dr. Andrew Mason, University of Alberta  
Dr. Derek McKay, University of Calgary  
Dr. Clarence Wong, University of Alberta

## Contact

ASG@buksa.com  
www.albertagastro.ca



Alberta Society of  
Gastroenterology

## Conference Secretariat

BUKSA Strategic Conference Services  
Suite 307, 10328 - 81 Avenue NW, Edmonton, AB T6E 1X2  
Tel.: 780.436.0983 x257  
Fax: 780.437.5984  
Email: ASG@buksa.com  
www.etchouches.com/ADDS13



**BUKSA**

## LEARNING OBJECTIVES:

- Communicate state-of-the-art knowledge in the diagnosis and treatment of ascites, inflammatory bowel disease and upper GI dysplasia
- Articulate the key findings of current research into the treatment of liver disease, luminal disease and IBD
- Provide an update on the use of probiotics in IBS treatment and on the use of anti-inflammatory drugs in the treatment of IBD
- Discuss the latest developments in the treatment and diagnosis of gastroenterological cancers, including hepatocellular carcinoma
- Describe how recent developments in translational science apply to clinical gastroenterological practice
- Share novel research strategies and initiatives being conducted across Canada
- Continue to build the network of basic and clinical investigators in order to promote translational and clinical research relating to gastrointestinal disease
- Learn how to better educate patients about the risks and benefits, as well as treatment and management options, for common GI diseases

## Accreditation:

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and has been approved by the Division of Continuous Professional Learning at the University of Alberta for a maximum of 12 hours of credit.

# SCHEDULE AT A GLANCE

## Friday, June 14

8:00 am - 4:30 pm	<b>SHAFFER AWARDS</b> Oral and Poster Presentations	<i>Mount Temple A</i>
3:00 - 4:00 pm	<b>Takeda Preconference Symposium on Ulcerative Colitis</b>	<i>Saddleback / Plain of Six Glaciers</i>
7:00 am - 7:30 pm	Registration Open	<i>Alpine Gallery</i>
4:30 - 6:30 pm	<b>PLENARY SESSION: State-of-the-Art Updates</b>	<i>Mount Temple A</i>
6:30 - 7:30 pm	Posters and Reception	<i>Alpine Gallery / Heritage Hall</i>
7:30 - 9:30 pm	Dinner, Awards Ceremony and ASG Awards	<i>Mount Temple B/C</i>

## Saturday, June 15

7:00 am - 1:00 pm	Registration Open	<i>Alpine Gallery</i>
7:00 - 8:00 am	<b>Janssen Breakfast Symposium: Maximizing Outcomes in GI</b>	<i>Beehive / Lakeshore</i>
7:00 - 8:00 am	<b>Vertex Breakfast Symposium on Hepatitis C</b>	<i>Saddleback / Plain of Six Glaciers</i>
8:15 - 10:15 am	<b>PLENARY SESSION: Landmark Updates</b>	<i>Mount Temple B/C</i>
10:15 - 10:30 am	Break	<i>Alpine Gallery / Heritage Hall</i>
10:30 am - 12:30 pm	<b>PLENARY SESSION: Updates in GI and Liver Cancer</b>	<i>Mount Temple B/C</i>

12:30 - 1:30 pm	<b>AbbVie Lunch Symposium: Patient Communication and Best Care in IBD</b>	<i>Saddleback / Plain of Six Glaciers</i>
12:30 - 1:30 pm	Lunch	<i>Mount Temple A</i>
1:30 - 6:30 pm	<b>Free Time</b>	
1:30 - 4:30 pm	Fellows' Exam Prep Course	<i>Beehive / Lakeshore</i>
6:30 - 11:00 pm	BBQ, Keynote and Dance	<i>Brewster Dance Barn</i>

## Sunday, June 16

7:00 am - 1:00 pm	Registration Open	<i>Alpine Gallery</i>
7:00 - 8:00 am	<b>Ferring Breakfast Symposium on IBD</b>	<i>Beehive / Lakeshore</i>
7:00 - 8:00 am	<b>Merck Breakfast Symposium on Hepatitis C</b>	<i>Saddleback / Plain of Six Glaciers</i>
8:15 - 10:00 am	<b>CONCURRENT SESSIONS: DDW and EASL/AASLD Updates</b>	<i>Beehive / Lakeshore &amp; Saddleback / Plain of Six Glaciers</i>
10:00 - 10:15 am	Break	
10:15 - 11:30 am	<b>CONCURRENT SESSIONS: DDW and EASL/AASLD Updates</b>	<i>Beehive / Lakeshore &amp; Saddleback / Plain of Six Glaciers</i>
11:30 am - 1:30 pm	ASG Annual General Meeting and Working Lunch	<i>Mount Temple B/C</i>
11:30 am - 1:30 pm	Guests' / Non-Members' Lunch	<i>Mount Temple A</i>
1:30 pm	Conference Ends / Travel Home	

# DETAILED PROGRAM

## Friday, June 14 - Preconference Events

8:00 am - 4:30 pm **SHAFFER AWARDS**

*Mount Temple A*

8:00 - 8:05 am

### **Welcome**

Dr. Paul Beck, Division of Gastroenterology and Hepatology, University of Calgary

8:05 - 8:45 am

### **Keynote Address: Tumor Microenvironment in Colitis-associated Carcinogenesis**

Accredited for 0.5 hours of MOC Section 1 credit

Dr. Laurence Egan, Department of Pharmacology and Therapeutics, National University Ireland, Galway

*This presentation will highlight recent advances in our understanding of the role played by non-cancer cells in the development and progression of colon cancer.*

#### **Learning Objectives:**

Following the presentation, attendees will be able to:

- Describe the role of non-cancer cells in tumorigenesis
- Explain the impact of DNA methylation on epithelial cells
- Explain the importance of cytokines in colon carcinogenesis

8:45 - 9:00 am

### **A Majority of Patients with Active Luminal Crohn's Disease Have Evidence of Significant Functional and Clinical Pulmonary Involvement**

Dr. Farhad Peerani, University of Alberta

9:00 - 9:15 am

### **Anti-OmpC and a Locus on Chromosome 8q24 Near MYC are Associated with Perianal Crohn's Disease**

Dr. Travis Murdoch, University of Calgary

9:15 - 9:30 am

### **NMR Urine Metabolomics in the Prediction of Response to Infliximab in Patients with Ulcerative Colitis and Crohn's Disease**

Miss Rae Foshaug, University of Alberta

9:30 - 9:45 am

### **Complication Rate of Serrated Adenoma Resection from the Proximal Colon**

Dr. Erin Ross, University of Calgary

- 9:45 - 10:00 am **Identification of Human Betaretrovirus Infection in Biliary Epithelial Cells from Patients with Autoimmune Liver Disease**  
Mr. Weiwei Wang, University of Alberta
- 10:00 - 10:15 am Nutrition Break *Heritage Hall*
- 10:15 - 10:30 am **Elucidating Intestinal Microbiota Components that Play a Protective or Deleterious Role During Clostridium Difficile Infections**  
Mr. Patrick Schenck, University of Calgary
- 10:30 - 10:45 am **Anti-TNF Dose Escalation in Inflammatory Bowel Disease**  
Dr. Christopher Ma, University of Alberta
- 10:45 - 11:00 am **Microbial Predictors of Postoperative Recurrence in Crohn's Disease**  
Mr. Kyle Lesack, University of Calgary
- 11:00 - 11:15 am **Characterizing the Role of IL-1 $\beta$  in Macrophage Handling of Citrobacter Rodentium Infection**  
Mr. Michael Bording-Jorgensen, University of Alberta
- 11:15 - 11:30 am **Giardia Duodenalis Cathepsin-like Cysteine Proteases Contribute to Cytoskeletal and Tight Junctional Injury**  
Mr. Amol Bhargava, University of Calgary
- 11:30 am - 1:00 pm Lunch and Poster Viewing  
Poster Judging *Heritage Hall*
- 1:00 - 1:45 pm **CAG Visiting Research Scholar Keynote: Role of Autophagy in Inflammatory Bowel Disease**  
Accredited for 0.5 hours of MOC Section 1 credit  
Dr. Nicola Jones, Department of Gastroenterology, Hepatology and Nutrition at the Hospital for Sick Children; Department of Pediatrics, University of Toronto  
*Recent advances in inflammatory bowel disease (IBD) research suggest that people with inflammatory bowel disease may*

*respond differently to the normal bacteria that reside in the intestine and that this contributes to the development of disease. Why individuals respond differently is not known. A large number of studies have consistently found that changes in ATG16L1 that is needed for the autophagy pathway are associated with the development of Crohn's disease. This presentation will review the autophagy pathway and the current understanding of how the autophagy pathway might mediate inflammatory bowel disease.*

**Learning Objectives:**

Following the presentation, attendees will:

- Have a general understanding of autophagy
- Understand how autophagy may be involved in inflammatory bowel disease
- Be able to weigh the potential therapeutic implications of this research

1:45 - 2:00 pm	<b>Colonic MUC2 Mucin Regulates the Expression and Antimicrobial Activity of <math>\beta</math>-defensins</b> Dr. Eduardo Cobo, University of Calgary
2:00 - 2:15 pm	<b>Is Translocation of Commensal Bacteria One of the Mechanisms Leading to Post-Infectious Irritable Bowel Syndrome in Experimental Giardiasis?</b> Ms. Amy Halliez, University of Calgary
2:15 - 2:30 pm	<b>Protecting the Gut Against Clostridium Difficile Toxin Induced Injury: A Role for Intestinal Growth Factor</b> Dr. Basmah Alhassan, University of Calgary
2:30 - 2:45 pm	<b>Patients with Primary Biliary Cirrhosis Make Cellular Immune Responses to Human Betaretrovirus</b> Ms. Mandana Rahbari, University of Alberta
2:45 - 3:00 pm	<b>Treatment with Cryopreserved Alternatively Activated Macrophages Attenuates DNBS Colitis</b> Ms. Gabriella Leung, University of Calgary
3:00 - 4:30 pm	Break & Poster Viewing Poster Judging

*Heritage Hall*



3:00 - 4:00 pm

**Takeda Symposium**

*Saddleback / Plain of Six Glaciers*

## **THE UNMET NEED IN ULCERATIVE COLITIS**

Sponsored by:



Session chair: Dr. Remo Panaccione, Division of Gastroenterology and Hepatology, University of Calgary

### **Learning Objectives:**

Following the presentations, attendees will be able to:

- Describe the natural history of ulcerative colitis
- Review the current treatment landscape for UC
- Understand the current treatment paradigm and the unmet need in UC
- Review the future opportunities for treatments in UC

3:00 - 3:25 pm

### **The History of UC and Current Treatment Paradigms**

Dr. Geert D'Haens, Inflammatory Bowel Disease Centre, Academic Medical Centre, Amsterdam

3:25 - 3:50 pm

### **Future UC Treatment: Addressing the Unmet Need**

Dr. Brian Feagan, Division of Gastroenterology, University of Western Ontario

3:50 - 4:00 pm

Q&A

## **Friday, June 14 - Alberta Digestive Disease Summit**

4:30 - 6:30 pm

### **STATE OF THE ART UPDATES**

*Mount Temple A*

Session Chair: Dr. Tara Chalmers-Nixon, Division of Gastroenterology and Hepatology, University of Calgary

4:30 - 5:00 pm

### **State of the Art in Liver: The Management of Ascites Due to Cirrhosis**

Dr. Bruce Runyon, Division of Digestive Diseases, UCLA Santa Monica Medical Center

*Ascites is the most common of the Big Three Complications of cirrhosis; the other two being hepatic encephalopathy and variceal hemorrhage. The speaker will discuss the importance of ascitic fluid analysis in ruling in portal hypertension as the cause of ascites formation and in ruling out bacterial infection. First-line treatment options include abstinence from alcohol (and baclofen to reduce alcohol craving), sodium-restricted diet and dual diuretics. Development of ascites is a landmark in the*

*natural history of cirrhosis and should prompt consideration of liver transplantation. Second-line options include discontinuation of drugs that reduce blood pressure, adding midodrine to support blood pressure, therapeutic taps, TIPS, and liver transplantation. Third-line options include Denver shunt and splenic artery embolization.*

**Learning Objectives:**

Following the presentation, attendees will be able to:

- Understand the importance of blood pressure in the management of ascites
- Understand 1st line, 2nd line and 3rd line treatments of ascites
- Understand the drugs and procedures to avoid in patients with ascites

5:00 - 5:10 pm

Q&A

5:10 - 5:40 pm

**State of the Art in IBD: Biosimilars**

Dr. Geert D'Haens, Inflammatory Bowel Disease Centre, Academic Medical Centre, Amsterdam

*A biosimilar is a biological medicine that enters the market subsequent to expiration of the patent of an original reference product. The term 'biosimilar' is recognised by all regulators, but synonyms include 'similar biotherapeutic product' (WHO) and 'subsequent-entry biologic' (Canada). Biopharmaceutical agents are derived from living cells or organisms and are usually complex proteins. Therefore, regulators are establishing novel specific approval pathways for biosimilars that differ from those for chemical generics. Since the first approval in 2005, several biosimilars of somatropin (human growth hormone), filgrastim (granulocyte colony-stimulating factor, G-CSF) and epoetin (erythropoietin) have become available in Europe. Currently, 12 biosimilars are authorized in the European market, and numerous others, including monoclonal antibodies (mAbs), have applied for authorization. This subject has received increasing attention in gastroenterology, because the patent on infliximab is due to expire and regulatory approval for two biosimilar infliximabs have already been filed for to the European Medicines Agency (EMA). One of these molecules is already available for patient care in South Korea. We will discuss medical and regulatory challenges associated with the appearance of these agents.*

**Learning Objectives:**

Following the presentation, attendees will be able to:

- Understand how biosimilars differ from the original biological
- Understand the manufacturing process of therapeutic antibodies
- Understand the risks and potential benefits of switching from conventional to biosimilar biologicals

5:40 - 5:50 pm	Q&A	
5:50 - 6:20 pm	<p><b>State of the Art in Luminal: Detection and Treatment of Upper GI Dysplasia</b></p> <p>Dr. Kenneth Wang, Department of Gastroenterology and Hepatology, Mayo Clinic</p> <p><i>Learning Objectives:</i></p> <p>Following the presentation, attendees will be able to:</p> <ul style="list-style-type: none"> <li>● Understand the use of Narrow Band Imaging (NBI) in the detection of dysplasia in Barrett's Esophagus</li> <li>● Describe endoscopic magnification techniques currently available</li> </ul>	
6:20 - 6:30 pm	Q&A	
6:30 - 7:30 pm	<p>Poster Viewing</p> <p>Wine and Cheese Reception</p>	<i>Alpine Gallery</i>
7:30 - 10:00 pm	<b>ASG NIGHT &amp; DINNER</b>	<i>Mount Temple B/C</i>

- President's Address  
 Shaffer Awards Ceremony  
 ASG Awards Ceremony:
- Sherbaniuk/Hershfield Award for Distinguished Service
  - Distinguished Educator Award
  - Distinguished Researcher Award

## Saturday, June 15

7:00 - 8:00 am	<p><b>Janssen Breakfast Symposium</b></p> <p><b>MAXIMIZING OUTCOMES IN GI</b></p>	<i>Beehive / Lakeshore</i>
----------------	---	----------------------------

Accredited for 1 hour of MOC Section 1 credit

Breakfast sponsored by:



Session chair: Dr. Shane Devlin, Inflammatory Bowel Disease Clinic, The University of Calgary

### When to use Biologics?

Dr. Geert D'Haens, Inflammatory Bowel Disease Centre, Academic Medical Centre, Amsterdam

## **Management of Chronic Constipation: The new 5HT4 prokinetic agent, prucalopride, and its cardiovascular safety**

Dr. Louis Liu, University Health Network, Toronto

*Chronic constipation is a common illness, yet its management is often challenging to physicians and dissatisfying to the patients. This presentation discusses the role of a new enterokinetic agent, prucalopride, in the treatments of chronic constipation. Approximately 45% of the patients with chronic constipation find the commonly used laxatives are ineffective or unable to be tolerated due to their side effects. Prucalopride has shown to be effective and well tolerated by patients with chronic constipations as well as to improve these patients' quality of life and abdominal symptoms. The cardiovascular safety profile of prucalopride will be discussed and compared with previous enterokinetics (cisapride and tegaserod).*

### **Learning Objectives:**

At the end of the presentation, attendees will be able to:

- Develop an approach in the management of chronic constipation
- Understand the MOA of prucalopride as a new enterokinetic agent
- Be familiar with the results of the pivotal trials of prucalopride in the management of chronic constipation
- Appreciate the common side effects of prucalopride with a focus on its cardio-vascular safety profile

7:00 - 8:00 am

**Vertex Breakfast Satellite Symposium  
ON HEPATITIS C**

*Saddleback /  
Plain of Six Glaciers*

Sponsored by:



Session chair: Dr. Robert Bailey, Division of  
Gastroenterology, University of Alberta

### **Clinical Importance of Virologic Cure**

Dr. Mark Swain, Gastrointestinal Research Group,  
University of Calgary

### **Treating Now: Practical Considerations to Manage HCV Genotype 1**

Dr. Jordan Feld, Division of Gastroenterology,  
The University of Toronto

*The development of the first generation of direct acting antivirals (DAAs) for hepatitis C virus (HCV) infection has been a major advance. Treatment success rates have improved markedly across most groups of patients with genotype 1 infection. However, although these agents provide clear benefit, they have also added significant complexity to therapy. Treatment regimens are more complicated, adverse events are more frequent and more severe and drug interactions are a new concern. As we have gained real-world experience with boceprevir and telaprevir, we have learned how to overcome many of these challenges. Practical tips on managing adverse events and getting patients, particularly those with severe liver disease, through therapy, will be discussed.*

#### **Learning Objectives:**

Following the session, participants will be able to:

- Understand the importance of patient selection and proper pre-treatment evaluation prior to starting protease-inhibitor-based antiviral therapy for hepatitis C virus (HCV) infection.
- Appreciate the severity of adverse events that may occur in patients with advanced liver disease treated protease-inhibitor-based therapy.
- Develop an approach to clinical management including dealing with adverse events during protease-inhibitor-based therapy.

#### **Case Presentations and Panel Discussion**

Dr. Robert Bailey, University of Alberta

Panelists:

Dr. Mark Swain, University of Calgary

Dr. Jordan Feld, University of Toronto

8:15 - 10:15 am

### **LANDMARK UPDATES**

*Mount Temple B/C*

8:15 - 8:35 am

Session chair: Dr. Robert Bailey, Division of Gastroenterology, University of Alberta

#### **Landmark Updates in Hepatitis C and Liver Disease**

Dr. Jordan Feld, Division of Gastroenterology, The University of Toronto

*In this session, Dr. Feld will be reviewing four papers of importance in the field of hepatology in the past year. These will include "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options" (Jacobson et al NEJM Apr 23, 2013), "Sofosbuvir for previously untreated chronic hepatitis C infection" (Lawitz, NEJM Apr 23, 2013), "Treatment of HCV infection by targeting microRNA" (Janssen et al Mar 27*

2013) and “Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.” (*Villa E Gastroenterology*. 2012 Nov;143(5):1253-60). Dr. Feld will discuss the importance of each paper with a critical appraisal of the strengths and weaknesses as well as the relevance to clinical practice.

**Learning Objectives:**

Following the presentation, attendees will be able to:

- Appreciate the importance of novel therapies for treating hepatitis C virus infection.
- Understand the rationale behind targeting microRNAs as a therapeutic strategy.
- Appreciate how anticoagulant therapy may be useful in patients with advanced cirrhosis.

8:35 - 8:45 am

Q&A

8:45 - 9:05 am

**Luminal Update**

Dr. Robert Enns, Division of Gastroenterology, University of British Columbia

*In this review of luminal gastrointestinal disorders, we will assess some of the latest technologies to be used in the GI tract. We will attempt to review at least seven to eight abstracts either from DDW or papers that have recently/soon to be published with advanced techniques/technology that may apply to everyone's clinical practice. The discussion will be fast paced, covering a lot of ground and hopefully reviewing what is new in obscure GI bleeding, non variceal GI bleeding, endoscopic stenting and small bowel investigations. Papers will be reviewed from DDW as well as Gastrointestinal Endoscopy recent publications.*

**Learning Objectives:**

Following the session, participants will be able to become familiar with some up and coming new technology as it applies to specific areas of gastroenterology in areas of:

- Obscure gastrointestinal bleeding
- ERCP
- Endoscopic therapies of gastrointestinal non variceal bleeding

9:05 - 9:15 am

Q&A

9:15 - 9:35 am

**IBD Update**

Dr. Maria Abreu, Division of Gastroenterology, University of Miami Health System

9:35 - 9:45 am

Q&A

9:45 - 10:05 am

### Translational Science Updates

Dr. Laurence Egan, Department of Pharmacology and Therapeutics, National University Ireland, Galway

*This presentation will review some key recently published papers that have identified new clinically important molecular discoveries relevant to clinical gastroenterology practice.*

#### **Learning Objectives:**

Following this presentation, delegates will be able to:

- Explain the molecular factors that recent research have shown are important in disease pathogenesis;
- Articulate ways in which the research on molecular factors in disease pathogenesis applies to their clinical gastroenterology practice

10:05 - 10:15 am

Q&A

10:15 - 10:30 am

Break

*Heritage Hall / Alpine Gallery*

10:30 am - 12:30 pm

### UPDATES IN GI AND LIVER CANCER

*Mount Temple B/C*

Session Chair: Dr. Kelly Burak, Southern Alberta Liver Transplant Clinic and Division of Gastroenterology and Hepatology, University of Calgary

10:30 - 11:00 am

#### **Cancer in IBD**

Dr. Peter Irving, Guy's and St. Thomas' Hospitals, London, UK

*In this session, we shall review the interaction between IBD and malignancy. A number of areas will be covered. First, the effects of IBD on cancer risk both within and without the gastrointestinal tract will be addressed as will ways in which it may be possible to mediate the risks of IBD-related cancer. Second, the effects of drug therapy on cancer risk will be discussed and consideration will be given to whether risk stratification is possible. Finally, we will review the difficult issue of how to manage IBD in patients with a history of malignancy or who have active cancer.*

#### **Learning Objectives:**

Following this presentation, delegates will be able to:

- Understand the risk of malignancy associated with IBD and how to ameliorate that risk
- Understand how drugs used to treat IBD may increase the risk of developing malignancy
- Be familiar with the challenges of managing IBD in patients with active malignancy or who have a past history of cancer

11:00 - 11:10 am Q&A

11:10 - 11:40 am **Hepatocellular Carcinoma**

Dr. Phillip Johnson, Translational Medicine, University of Liverpool

*Worldwide, hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading cause of cancer-related death. Over 80% of the annual burden of around 750,000 cases occurs in China, SE Asia or sub-Saharan Africa. In these areas, the primary aetiological agent is chronic hepatitis B virus (HBV) infection, contracted at birth or during the first few years of life. In the West, about 40% of cases are attributable to chronic hepatitis C infection, a similar percentage to chronic alcohol consumption and the remainder are split between HBV, non-alcoholic fatty liver disease (NAFLD), and other types of cirrhosis. Diabetes is increasingly recognised prior to the development of HCC. Recent evidence from the US suggests that whilst cancer mortality is falling for most cancers it is rising rapidly for HCC.*

*Surveillance is now accepted to be essential to diagnose HCC early, at a time when it is potentially curable. The primary tool is ultrasound examination. Curative therapies include orthotopic liver transplantation, resection and ablative approaches. Although with the introduction of Sorafenib in 2007, a modest improvement in survival (from about seven to 10 months) has been achieved there has been little by way of advance over the last six years.*

*It remains surprising that well-structured surveillance programs are not more widely utilised. In most West countries, only a minority of patients with HCC are detected in surveillance programmes.*

**Learning Objectives:**

Following this presentation, delegates will be able to:

- Understand that detected early, hepatocellular carcinoma is a potentially curable disease
- Explain how effective surveillance of patients with chronic liver disease is the key to early diagnosis
- Describe the palliative options for advanced disease, which have minimal benefits

11:40 - 11:50 am Q&A

11:50 am - 12:20 pm **Current and Novel Endoscopic Therapies for Luminal Cancers**

Dr. Kenneth Wang, Department of Gastroenterology and Hepatology, Mayo Clinic



### **Learning Objectives:**

Following this presentation, delegates will be able to:

- Describe lesions that are amenable to mucosal resection
- Understand the risk of recurrence after ablative therapy
- Identify alternative treatments for ablative therapy

12:20 - 12:30 pm Q&A

12:30 pm Lunch *Mount Temple A*  
(For guests and those not attending the Lunch Symposium)

12:30 - 1:30 pm **Lunch Symposium** *Saddleback / Plain of Six Glaciers*

### **IMPROVING PATIENT COMMUNICATION AND UTILIZING BEST CARE PATHWAYS IN THE TREATMENT OF IBD**

Accredited for 1 hour of MOC Section 1 credit

Lunch sponsored by:

**abbvie**

Session Chair: Dr. Richard Fedorak, Division of  
Gastroenterology, University of Alberta

#### **Communicating Benefit and Risk to your Patients: How can we do it Better?**

Dr. Peter Irving, Guy's and St. Thomas' Hospitals,  
London, UK

*Over recent years, the number of options available for the treatment of IBD has increased markedly. In conjunction with this, there has been a shift in treatment paradigms towards early more aggressive treatment in appropriate patients in an attempt to alter the disease course. However, increased use of potentially toxic therapy is inevitably associated with increased risk of side-effects. Communicating the risks and benefits of treatment options in IBD is thus of tantamount importance. Communication has traditionally been neglected in the training of doctors and reviewing some of the pitfalls associated with explaining potentially difficult concepts to patients is, therefore, worthwhile. In addition, we shall cover some ways in which we can explain risk and benefit more clearly as well as how we can put risk in context.*

**Learning Objectives:**

Following this presentation, delegates will be able to:

- Understand the importance and value of communicating risk and benefit to patients with IBD
- Understand the potential pitfalls in the communication of risk and benefit to patients
- Understand how the use of graphical and pictorial material can enhance the communication of risk and benefit

**Networking and Future Best Care Pathways in Canadian IBD**

Dr. Remo Panaccione, Associate Professor, Division of Gastroenterology, University of Calgary

**Learning Objectives:**

Following the session, participants will be able to:

- Recognize the emerging trends in IBD care locally and nationally
- Articulate the importance of the multidisciplinary team in the management of IBD
- Recognize the importance of organizing IBD networks
- Understand the importance and value of communicating risk and benefit to patients with IBD
- Understand the potential pitfalls in the communication of risk and benefit to patients
- Describe how the use of graphical and pictorial material can enhance the communication of risk and benefit

1:30 - 6:30 pm

**Free Time**

1:30 - 4:30 pm

**FELLOWS' EXAM PREP COURSE**

*Beehive / Lakeshore*

Facilitator: Dr. Mani Kareemi, Division of Gastroenterology, University of Calgary

1:30 - 2:00 pm

Introduction, Course Objectives, Exam Format

2:00 - 2:30 pm

Guide to Covering Curriculum During Preparation

2:30 - 3:15 pm

Approach to SAQ Questions

3:15 - 4:00 pm

Approach to OSCE Stations

4:00 - 4:30 pm

Imaging Stations: Review

6:30 pm

**RECEPTION, BBQ DINNER,  
KEYNOTE PRESENTATION & DANCE**

*Brewster Dance Barn,  
Lake Louise*

6:15 - 7:00 pm

Ride Wagon or Walk to Barn

6:30 - 7:00 pm

Reception

7:00 pm

Dinner

8:00 pm

**Keynote: Above All Else**

Jamie Clarke, Adventurer and Entrepreneur

9:00 pm

Dance featuring the *Reuben Kincaid Band*

## Sunday, June 16

7:00 - 8:00 am

**Ferring Breakfast Symposium on IBD  
ULCERATIVE COLITIS:  
DIFFICULTIES WITH RELAPSE AND  
CONCOMITANT IBS SYMPTOMS**

*Beehive / Lakeshore*

Accredited for 1 hour of MOC Section 1 credit;

Breakfast sponsored by:



**Learning Objectives:**

Following the Symposium, attendees will be able to:

- Review the data supporting adjunctive treatment (oral and rectal 5ASA) including new data from MOTUS
- Contemplate the switch to or addition of infliximab or azathioprine for patients with ulcerative colitis
- Review the proposed mechanisms of action for probiotics in patients with post-UC IBS symptoms
- Understand the extent to which patients with IBD experience IBS, and the frequent challenge of separating symptoms of one from the other
- Understand the relevance of strain-specific probiotic selection
- Explain the evidence supporting the use of probiotic agents in some patients with quiescent colitis and persistent IBS symptoms

7:00 - 7:05 am

**Introduction**

Dr. Remo Panaccione, Division of Gastroenterology and Hepatology, University of Calgary

- 7:05 - 7:30 am **UC treatment after 5ASA Failure or Partial Response**  
Dr. Maria Abreu, Division of Gastroenterology,  
University of Miami Health System
- 7:30 - 7:50 am **Post UC IBS symptoms: Is there a role for Probiotics?**  
Dr. Connie Switzer, Division of Gastroenterology,  
University of Alberta
- 7:50 - 8:00 am **Q&A**

7:00 - 8:00 am **Merck Breakfast Symposium**  
**REAL LIFE CASE EXPERIENCES**  
**WITH TRIPLE THERAPY IN PATIENTS**  
**WITH HEPATITIS C**

*Saddleback / Plain  
of Six Glaciers*

Breakfast sponsored by:



***Learning Objectives:***

Following the Symposium, attendees will be able to:

- Understand the effectiveness of triple therapy in a real-life setting
- Understand the importance of patient selection and patient management during triple therapy in a real life setting including variables associated with anemia, discontinuation rates, and markers to predict outcome such as platelets and albumin
- Discuss the importance of treatment of less challenging patients with early fibrosis to prevent future management problems

**Introduction - Case Studies**

Dr. Samuel Lee, Gastrointestinal Research Group,  
University of Calgary and Foothills Hospital

**The Beginning of the End for HCV or the End of the Beginning?**

Dr. Doug Dieterich, Department of Medicine - Liver  
Diseases, ICAHN School of Medicine at Mount Sinai

8:15 - 11:05 am

**Concurrent Sessions**  
**DDW AND EASL UPDATES**

**IBD / GI**

*Beehive / Lakeshore*

8:15 - 8:20 am

**Welcome Comments**

Session Chair: Dr. Richard Fedorak, Division of Gastroenterology, University of Alberta

8:20 - 9:00 am

**Keynote: IBD Pathogenesis**

Dr. Maria Abreu, Division of Gastroenterology, The University of Miami

9:00 - 9:20 am

**Motility**

Dr. Adriana Lazarescu, Division of Gastroenterology, University of Alberta

9:20 - 9:40 am

**Therapeutic Endoscopy**

Dr. Rachid Mohamed, Division of Gastroenterology and Hepatology, University of Calgary

9:40 - 10:00 am

**Small Bowel (non-IBD)**

Dr. Decker Butzner, Department of Pediatrics and Gastrointestinal Research Group, University of Calgary

10:00 - 10:15 am

Nutrition Break

10:15 - 10:35 am

**Crohn's Disease Update: Clinical Therapeutics for 2013**

Dr. Richard Fedorak, Division of Gastroenterology, University of Alberta

10:35 - 10:55 am

**Esophageal Disease**

Dr. Milli Gupta, Division of Gastroenterology and Hepatology, University of Calgary

10:55 - 11:15 am

**Ulcerative Colitis**

Dr. Shane Devlin, Inflammatory Bowel Disease Clinic, University of Calgary

11:15 - 11:20 am

**Closing Comments**

11:20 - 11:30 am

Room Change

**LIVER**

*Saddleback / Plain of Six Glaciers*

8:15 - 8:20 am

**Welcome Comments**

Session Chair: Dr. Kelly Burak, Southern Alberta Liver Transplant Clinic and Division of Gastroenterology and Hepatology, University of Calgary

8:20 - 9:00 am	<p><b>Keynote: Latest Management of Hepatitis B Virus</b> Dr. Harry Janssen, Division of Gastroenterology, University of Toronto</p> <p><i>Learning Objectives:</i></p> <p>Following the presentation, participants will be able to:</p> <ul style="list-style-type: none"> <li>● Explain when to treat HBV infection</li> <li>● Describe the available treatment options for HBV infection</li> <li>● Understand the long-term effects and outcomes to be expected following HBV treatment</li> </ul>
9:00 - 9:20 am	<p><b>Hepatitis C</b> Dr. Mark Swain, Gastrointestinal Research Group, University of Calgary</p>
9:20 - 9:40 am	<p><b>Autoimmune Liver Disease</b> Dr. Andy Mason, Centre of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta</p>
9:40 - 10:00 am	<p><b>Pediatrics and Metabolic Liver Disease</b> Dr. Susan Gilmour, Department of Pediatrics, University of Alberta</p>
10:00 - 10:15 am	Nutrition Break
10:15 - 10:35 am	<p><b>NAFLD / ETOH</b> Dr. Saumya Jayakumar, Division of Gastroenterology and Hepatology, University of Calgary</p>
10:35 - 10:55 am	<p><b>Cirrhosis Complications</b> Dr. Puneeta Tandon, Division of Gastroenterology, University of Alberta</p>
10:55 - 11:15 am	<p><b>Liver Transplantation</b> Dr. Vince Bain, Division of Gastroenterology, University of Alberta</p>
11:15 - 11:20 am	<b>Closing Comments</b>
11:20 - 11:30 am	Room Change

11:30 am - 1:30 pm **Working Lunch**  
**ASG ANNUAL GENERAL MEETING**

*Mount Temple B/C*

11:30 am - 1:30 pm Guests' Lunch

*Mount Temple A*

1:30 pm Travel Home

## S P E A K E R S

### Dr. Maria Abreu



Dr. Maria T. Abreu completed a medical degree at the University of Miami School of Medicine, where she served as Student Council President and was inducted into the Iron Arrow Honor Society. Her postdoctoral training included internship and residency in medicine at the Brigham and Women's Hospital in Boston, Massachusetts, clinical and research fellowship in gastroenterology at the University of California, Los Angeles (UCLA), and training in molecular and cancer biology at UCLA.

Dr. Abreu is a Diplomat of the National Board of Medical Examiners, the American Board of Internal Medicine, and the American Board of Gastroenterology and a Fellow of the American College of Physicians. She served as Chair of the Underrepresented Minorities Committee of the American Gastroenterological Association (AGA) and is now Chair of the Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section of the AGA Institute Council. She is a member of the AGA Public Affairs and Advisory Committee, the American College of Gastroenterology's Women's Committee, and the Crohn's and Colitis Foundation of America (CCFA). She is on the Board of the Florida Chapter of the CCFA and in 2009 was recognized for her education, support, and advocacy for this organization. Dr. Abreu was selected Co-Director of the AGA's 2011 Spring Postgraduate course, and she was also named President-Elect of the Florida Gastroenterology Society. Dr. Abreu was elected to the American Society for Clinical Investigation in 2010 and she is listed in Castle Connolly as one of America's Top Doctors.

### Dr. Vince Bain



Dr. Vince Bain is currently Professor of Medicine at the University of Alberta in the Department of Medicine and is serving as the Medical Director of the University of Alberta Liver Transplant Program. This program includes eight hepatologists, and three transplant surgeons in Edmonton plus a dedicated Southern Alberta Liver Transplant Team in Calgary. The program completes about 70 transplants per year including live donor transplants and follows hundreds of successfully transplanted patients. Research interests in transplantation include

immunosuppression drug trials, post-transplant disease recurrence and post-transplant biliary complications.

## Dr. Decker Butzner

---



Dr. Decker Butzner is a Professor and past Head of the Division of Gastroenterology & Nutrition at the Alberta Children's Hospital and The University of Calgary. He has over 30 years of experience in the field of pediatric gastroenterology, including basic science and clinical research programs. He is a member of the Calgary and National Professional Advisory Boards for the Canadian Celiac Association.

## Jamie Clarke

---



Jamie Clarke grew up in Calgary, Canada in a family that loved to travel to the nearby Rocky Mountains to hike and ski. From a young age, Jamie would come along, pulled in a sled by the family's two malamutes. Clarke remembers hiking in his telemark boots as a child because children's hiking boots were not available. As a teenager, Clarke sought out mountains to ski up and down, just "looking for good terrain, to get out and have fun." He started reading books about outdoor adventures such as Chris Bonington's

*Annapurna*, Tom Horbein's *The West Ridge* and Don Starkell's *Paddle to the Amazon*. Mt. Everest soon captured Jamie's imagination.

In 1991, Jamie traveled to Mt. Everest with the Canadian expedition Climb For Hope. A team of 21 members climbed the north side of the mountain, making it to over 25,000 ft before bad weather forced them to turn back. Upon his return to Canada, Clarke immediately began planning and fundraising his return to Everest. The 1994, Lungs Without Limits expedition was for the Alberta chapter of the Canadian Lung Association. Clarke spent the years leading up to the expedition fundraising by speaking to students about his previous trip to Everest. The North American team of 14 climbed the north route, making it within 150m of the summit before poor weather and altitude sickness forced them to descend. Following his return from the 1994 expedition, Clarke once again began planning and fundraising to return to Mt. Everest. A team of about a dozen approached from the south side of Everest, summiting on May 23, 1997.

In 2007, Jamie began to plan a fourth return to Everest. Clarke fundraised by touring across North America, speaking about his previous expeditions at colleges and universities. The Climb With Us expedition focused on inspiring observers and gear innovation. The Champion Super Suit was designed for the expedition to be lightweight, flexible, and warmer than down; especially in high-wind situations that compress down to the point of being completely ineffective. Jamie and his team of six summited Everest from the south side on May 17, 2010.



## Dr. Geert D’Haens

---



Dr. Geert D’Haens is a Professor of Gastroenterology at the Academic Medical Center at the University of Amsterdam. After graduating from the University of Leuven, Belgium, he was trained in gastroenterology, gastrointestinal endoscopy and inflammatory bowel diseases at the University Hospitals in Leuven and at the University of Chicago Hospitals under the mentorship of Paul Rutgeerts and Steven Hanauer, respectively. He finished his PhD thesis in 1996 on mechanisms causing postoperative recurrence of Crohn’s disease. After that, most of his research efforts went into the mechanism of action of new IBD drugs, the development of endoscopic endpoints and surrogate markers for IBD and the effect of early intervention with anti-TNF. In 1999, he was one of the founders of ECCO, the European Crohn’s and Colitis Organization. Currently, Dr. D’Haens leads a group of 35 IBD researchers in the Academic Medical Centre. He is also Director of European Operations of Robarts Clinical Trials and scientific secretary of IOIBD, the International Organization for the Study of IBD.

## Dr. Doug Dieterich

---



Dr. Doug Dieterich is currently Professor of Medicine in the Division of Hepatology and also Director of Continuing Medical Education in the Department of Medicine at Mount Sinai School of Medicine, New York. He has a triple appointment in the divisions of Liver Disease, Gastroenterology, and Infectious Diseases. After graduating from Yale University and receiving his Doctorate of Medicine from New York University of Medicine, he completed his internship and residency in Internal Medicine at the Bellevue Hospital Center in New York where he was also a fellow in the Division of Gastroenterology. He became Clinical Assistant Professor of medicine and then a Clinical Associate Professor of Medicine, both at the New York University. Dr. Dieterich is an investigator for several ongoing studies evaluating the safety and efficacy of various antiviral treatment regimens for chronic hepatitis B & C.

## Dr. Shane Devlin

---



Dr. Shane Devlin graduated from the University of Manitoba Faculty of Medicine in 1999 before coming to the University of Calgary to complete his internal medicine residency and gastroenterology fellowship, which he completed in 2004. He then went on to complete an advanced clinical and research fellowship in inflammatory bowel disease at Cedars-Sinai Medical Center in Los Angeles, CA. Since 2006, Dr. Devlin has been part of the inflammatory bowel disease centre at the University of Calgary and actively participates in clinical trials for various therapeutic agents in IBD. He is also the post-graduate training program director for the adult gastroenterology program at the University of Calgary.

## Dr. Laurence Egan

---



Professor Laurence Egan graduated from University College Galway in 1990 (M.B., B.Ch., B.A.O.), and completed internship, house officer and registrar training, based at University College Hospital Galway. He received Membership of RCPI in 1992, and Masters in Medical Science from UCG in 1994. From 1994 to 1999, at the Mayo Clinic in Minnesota he completed further training in Internal Medicine, Clinical pharmacology & Gastroenterology, receiving American Board certification in those three disciplines. NUI Galway

conferred an MD in 1999. Professor Egan then undertook post-doctoral training from 2000 to 2002, in the Laboratory of Mucosal Immunology at the University of California, San Diego, before returning to the Mayo Clinic to take up a consultancy in Gastroenterology, with joint appointment in the Department of Molecular Pharmacology and Experimental Therapeutics. His research focuses on molecular characterization of signaling pathways involved in intestinal epithelial cell stress, death and malignant transformation. In 2005, Professor Egan was recruited by NUI Galway and the Health Service Executive West as Professor of Clinical Pharmacology/Consultant Clinical Pharmacologist and Head of the Department of Pharmacology & Therapeutics, a position he took up in August 2005.

## Dr. Robert Enns

---



Dr. Robert Enns graduated from University of British Columbia and completed a rotating internship at Royal Columbian Hospital. After two years as a Family Physician in rural British Columbia, he completed his internal medicine training at the University of British Columbia followed by Gastroenterology and Therapeutic Endoscopy training in Calgary and Duke University Medical Center respectively. He took up a faculty appointment at St. Paul's Hospital, University of British Columbia in 1998 and was appointed Clinical Professor of Medicine in 2010.

Dr. Enns is presently Division Head for Gastroenterology at St. Paul's Hospital (2000-2007), Medical Lead for Colon Check Program for Vancouver Coastal, Director of the Annual GI Forum in Vancouver (entering its 12 year of education in GI), and VP Clinical Affairs for the Canadian Association of Gastroenterology. He has also been the Director of the Gastrointestinal Research Institute (GIRI) in British Columbia for the last eight years, and is presently an Associate Editor for Gastrointestinal Endoscopy.

Dr. Enns has participated in numerous consensus conferences and working groups on endoscopy, gastroesophageal reflux disease (GERD), Non-steroidal anti-inflammatory drugs, colon cancer screening, endoscopy credentialing, colonoscopy standards and upper gastrointestinal bleeding.

## Dr. Richard Fedorak

---



Dr. Richard N Fedorak is Associate Vice President (Research) for the University of Alberta, Edmonton, Alberta, Canada and Professor of Medicine in the Division of Gastroenterology. In addition, he serves as Director for the Centre of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR) and Director of the Northern Alberta Clinical Trials and Research Centre (NACTRC). Outside of the University, Dr. Fedorak is President, Canadian Digestive Health Foundation (CDHF) and Chairman, Research Committee, World Gastroenterology Organization.

Dr. Fedorak received his medical degree with First Class Honours from the University of Alberta, Edmonton, Alberta, Canada. His postdoctoral training included an internship at the University of Western Ontario, in London, Ontario, and residency training in General Internal Medicine at the University of Toronto. His Gastroenterology Clinical and Research Fellowship training was carried out at the University of Chicago and Columbia University, New York. In 1987, Dr. Fedorak returned to the University of Alberta as an Alberta Heritage Foundation for Medical Research Clinical Investigator.

A recipient of numerous awards, research fellowships and grants, Dr. Fedorak is a recognized expert in inflammatory bowel disease. He has an active basic gastrointestinal research laboratory in the area of mucosal immunology, inflammation, and membrane function and structure. In 2008, Dr. Fedorak was appointed Fellow, Royal College of Physicians, London, in 2009 Fellow, Canadian Academy of Health Sciences and in 2011 Fellow of the Royal Society of Canada.

## Dr. Jordan Feld

---



Dr. Jordan Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld completed a clinical research fellowship in hepatology and then spent four years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health.

Dr. Feld returned to Toronto to join the faculty of the University of Toronto as an Assistant Professor of Medicine and clinician-scientist based at the Toronto Western Hospital Liver Center and the Sandra Rotman Centre for Global Health. His laboratory focuses on understanding treatment non-response in hepatitis C infection and more broadly on understanding the antiviral immune response with the goal of developing new strategies for the treatment of viral hepatitis.

## Dr. Susan Gilmour

---



Dr. Susan Gilmour, Associate Professor, Division of Pediatric Gastroenterology and Nutrition was appointed to the position of Chair, Department of Pediatrics, University of Alberta and Regional Program Clinical Director for the Stollery Children's Hospital in July 2009. She is also the Director for the Pediatric Liver Transplant Program at Alberta Health Services Stollery Children's Hospital.

Dr. Gilmour joined the Faculty of Medicine and Dentistry, University of Alberta in 1997 after completing her pediatrics residency and a two year research fellowship at The Hospital for Sick Children in Toronto. After arriving at the University of Alberta she redeveloped the Division of Gastroenterology and Nutrition and created the residency program in her subspecialty.

Dr. Gilmour completed an MSc degree in Public Health Science with research in epidemiology, at the University of Alberta in 2005. Her primary research interest is in the area of functional outcomes in liver transplants in children. She studies growth and development, and health-related quality of life in children following transplant.

## Dr. Milli Gupta

---



Dr. Milli Gupta is a Clinical Assistant Professor in the Section of Gastroenterology at the University of Calgary. She received her Medical Degree from the University of Western Ontario (UWO). She completed her Internal Medicine and Gastroenterology residencies at the University of Alberta, followed by an Advanced Esophageal Fellowship at Mayo Clinic, Rochester. Dr. Gupta will be based at South Health Campus.

## Dr. Peter Irving

---



Dr. Peter Irving is a Consultant Gastroenterologist specialising in IBD at Guy's and St Thomas' Hospital in London. He studied medicine at Cambridge University and The London Hospital Medical College and trained in Gastroenterology at Barts and the London and University College Hospital. His doctoral thesis, performed under the supervision of Professor David Rampton, was entitled 'Platelet-Leucocyte Aggregation in Inflammatory Bowel Disease'. He also spent a further period of research

with Professor Peter Gibson at Monash University, Melbourne. He has published three books on inflammatory bowel disease and over 50 book chapters and papers. He is a member of BRIDGE, an international IBD research group and his research interests cover a number of clinical and basic science areas. He is on the council of the IBD section of the British Society of Gastroenterology and is UK national representative to ECCO.

## Dr. Harry Janssen

---



Dr. Harry Janssen is Professor of Medicine, Francis Family Chair in Hepatology and Head of the Liver Clinic at Toronto Western and Toronto General Hospital, University Health Network, Toronto, Canada. He graduated from medical school at the Radboud University of Nijmegen, the Netherlands. During his study, he spent one year as research fellow in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in chronic hepatitis B. He then trained in Internal Medicine at Leiden University Medical Center and in Gastroenterology & Hepatology at Rotterdam Erasmus University Medical Center. Following his registration as Gastroenterologist, he returned to the Mayo Clinic for a research fellowship in Hepatology at the Center of Basic Research in Digestive Diseases. In 2001, he became a staff member and, in 2006, he was appointed as full professor of Hepatology and Chief of the Section Liver Diseases and Transplantation in Rotterdam.

As principle investigator, Professor Janssen coordinated numerous European and global multicenter studies on antiviral treatment for chronic viral hepatitis. He was awarded a Clinical Fellowship and an Innovative Research grant from the Netherlands Organisation of Scientific Research to study strategies of immune control in viral hepatitis and published many international articles on this subject. Professor Janssen has been chairman of the Dutch Association of Hepatology and was elected as Rising Star in Gastroenterology and Hepatology by the Association of the National European Societies of Gastroenterology. He has been member of the editorial board of Hepatology, Journal of Hepatology and Best Practice in Gastroenterology. He has published over 260 original peer-reviewed papers. In addition to his longstanding expertise in antiviral therapy of chronic viral hepatitis, professor Janssen is a leading scientist in the field of vascular disorders of the liver.

## Dr. Saumya Jayakumar

---



Dr. Saumya Jayakumar completed medical school at the University of Manitoba before completing an Internal Medicine Residency and a Gastroenterology Fellowship at the University of Western Ontario in London. She then completed a Hepatology Fellowship at the University of Alberta in Edmonton before completing a clinical and research Fellowship focused on Non-Alcoholic Fatty Liver Disease at the University of Virginia in Charlottesville, Virginia. In January 2013, Dr. Jayakumar became the Fellowship Program Director for the Hepatology Fellowship at the University of Calgary.

## Dr. Philip Johnson

---



Dr. Philip Johnson qualified in Medicine at the University of Manchester and subsequently held posts as Senior House Officer at four major London Postgraduate Centres, including the Royal Marsden Hospital, before moving to the Liver Unit at King's College Hospital, London. Here he gained initial training in hepatology and an introduction to clinical and laboratory research.

After a two year appointment at Manchester Royal Infirmary as Senior Registrar in General Medicine and Gastroenterology,

Dr. Johnson returned to the Liver Unit at King's College Hospital, London (now The Institute of Liver Studies), as Senior Lecturer and Assistant Director, in charge of the newly built extension to the Unit, the Sheikh Zaid Centre. Here he published extensively on the management and pathogenesis of autoimmune hepatitis and on hepatocellular carcinoma.

In 1992, he moved to The Chinese University of Hong Kong where he was Professor of Clinical Oncology and Head of Department. He commissioned a new Cancer Centre (the Sir Y.K. Pao Centre for Cancer) involving over 300 researchers and built up the Comprehensive Clinical Trials Unit. Research included the first studies on circulating nucleic acids and the application of serum EBV DNA assay to the diagnosis and management of nasopharyngeal cancer.

Professor Johnson returned to the UK in 2002 to take the Chair of Oncology and Translational Research at the School of Cancer Sciences, University of Birmingham. He was also Director of the Cancer Research UK Clinical Trials Unit, one of the largest of its type in the Europe. In 2012, he moved to the University of Liverpool (as Chair in Translational Research) to continue his work on hepatobiliary cancer and biomarker discovery, a field in which he has published over 400 original papers, textbook chapters and reviews.

## Dr. Nicola Jones

---



Dr. Nicola Jones received her medical degree from the University of Toronto. She subsequently completed training in Pediatrics and Pediatric Gastroenterology, Hepatology and Nutrition at SickKids in Toronto and a PhD in Molecular and Medical Genetics at the University of Toronto. Dr. Jones accepted a faculty position as a clinician scientist and pediatric gastroenterologist at the Hospital for Sick Children in 1999 and was promoted to full professor and senior scientist in 2010.

Dr. Jones's research program focuses on host pathogen interactions with particular interests in *Helicobacter pylori* and understanding host microbe interactions in inflammatory bowel disease. Her laboratory is supported by funding from the Canadian Institute of Health Research, and Canadian Crohn's and Colitis Foundation. Dr. Jones' research has been recognized with the University of Toronto

Department of Pediatrics Young Investigator Award 2004, Canadian Association of Gastroenterology Young Investigator Award 2005 and Canadian Association of Gastroenterology Visiting Research Professorship.

Dr. Jones is passionate about research education and is currently the scientific director for the Canadian Child Health Clinician Scientist Program. She has served as the training program director for the Division of Gastroenterology/ Hepatology and Nutrition at SickKids as well as on the Nucleus Committee for the Royal College of Physicians and Surgeons (Gastroenterology). She has chaired numerous meetings for trainees emphasizing career development and research including Canadian Association of Gastroenterology Residents in Training, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition First Year Fellows Conference, and Canadian Association of Gastroenterology Research Topics in GI Disease. Dr. Jones' abilities as an educator have been recognized with a Canadian Association of Gastroenterology Young Educator Award 2009.

Dr. Jones has served as the research chair for the Canadian Crohn's and Colitis Foundation, a council member for the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition and is currently the VP secretary for Canadian Association of Gastroenterology.

## Dr. Adriana Lazarescu

---



Dr. Adriana Lazarescu is an assistant professor in the Division of Gastroenterology at the University of Alberta and the director of the GI Motility Lab at the University of Alberta Hospital in Edmonton, Alberta.

Dr. Lazarescu received her medical degree from the University of Toronto in Toronto, Ontario. She undertook an Internal Medicine residency at the University of Western Ontario in London, Ontario, followed by a Gastroenterology fellowship at Queen's University in Kingston, Ontario.

Dr. Lazarescu then completed a CIHR-funded clinical research fellowship in Esophageal Motility under the supervision of Dr. Daniel Sifrim at the Catholic University of Leuven in Leuven, Belgium.

Dr. Lazarescu's current clinical practice focuses largely on upper and lower GI tract motility disorders. Her research interests include functional imaging of the esophagus, gastroesophageal reflux disease, and anorectal manometry. She is also the director of the Gastroenterology Subspecialty Training Program at the University of Alberta.

## Dr. Samuel Lee

---



Dr. Samuel Lee is Professor of Medicine (Hepatology) at the University of Calgary. He received his MD from Memorial University, and then completed residency training in Internal Medicine and Gastroenterology at the University of Toronto. This was followed by a research fellowship at INSERM Unit 481 (Vascular Biology in Cirrhosis) in Paris. His laboratory research program is focused on cardiovascular abnormalities in cirrhosis and clinical research on viral hepatitis. He has served as President of the Canadian Association for Study of Liver, and served on several international and national committees including the AASLD Ethics Committee; he was also chairman of the International Ascites Club (2007-10) and editor-in-chief of the journal *Liver International* (2008-13). He is currently a councillor of the IASL Executive Committee. Dr. Lee has lectured in more than 30 countries. He has won several awards for teaching and research including the Queen Elizabeth II Golden Jubilee Medal.

## Dr. Louis Liu

---



Dr. Louis Liu grew up in Hong Kong and came to Canada in 1984. He completed his Bachelor, Masters and PhD in Engineering at McMaster University. He further pursued his medical training and received his Doctor of Medicine in 1998 at McMaster University. He completed his Internal Medicine Residency Training at the University of Toronto and his GI fellowship at McMaster University. Currently, Dr. Liu is an Assistant Professor at the University of Toronto (UoT) and a Gastroenterology Consultant at the University Health Network (UHN). His clinical expertise is in Neurogastroenterology and Intestinal Motility. He re-established the GI Clinical Motility Unit at TWH in 2008 and is currently the Director of the GI Clinical Motility Unit at UHN. He takes an active role in both undergraduate and post-graduate medical education as well as in the Royal College Gastroenterology Residency Training Programs. He is the Co-Director of the Metabolism and Nutrition Unit of the first-year MD Program in the UoT. He had been funded by CIHR, PSI (Physicians Services Incorporated) Foundation and CAG for his research.

## Dr. Andrew Mason

---



Dr. Andrew Mason is a Professor of Medicine and an Alberta Heritage Foundation for Medical Research Senior Scholar. He trained at the Liver Unit, Kings College Hospital, in London, England and then moved to Washington University, St. Louis as a Gastroenterology Fellow to train in molecular virology. At Ochsner Clinic Foundation, New Orleans he became the Medical Director of Liver Transplantation and an Assistant Professor in the Department of Medicine, Tulane University Medical Center.



He relocated to the University of Alberta in 2002; he is currently the Director Research for the Division of Gastroenterology and Director of The Applied Genomics Centre. In the laboratory, he has identified a human betaretrovirus in patients with the autoimmune liver disease, Primary Biliary Cirrhosis (PBC). His laboratory studies are now focused on investigating the prevalence of the human betaretrovirus in patients with PBC.

A causal association of virus and disease is being investigated using an in vitro model of PBC and a mouse model of disease, which is also being used to find novel combination antiviral therapies for patients with PBC. Dr. Mason is also principal investigator for an international, multi-center, double blind, randomized controlled trial using highly active anti-retroviral therapy to treat patients with PBC.

### Dr. Rachid Mohamed

---



Dr. Rachid Mohamed is a therapeutic endoscopist in Calgary, based out of the Peter Lougheed Center. Rachid completed medical school in Edmonton in 2005 and went on to an internal medicine residency at the University of Alberta. He moved home to Calgary in 2008 where he completed his gastroenterology fellowship followed by a year in therapeutic endoscopy. Currently, he performs ERCP at the Peter Lougheed Center and Endoscopic Ultrasound at the Foothills Medical Center. His interests lie in endoscopy, specifically education and advanced endoscopic procedures.

### Dr. Remo Panaccione

---



Dr. Remo Panaccione is currently an Associate Professor of Medicine at the University of Calgary and the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He has lectured across North America on various topics in inflammatory bowel disease and has delivered over 120 lectures in the last five years.

He is the author of many peer-reviewed articles and book chapters on inflammatory bowel disease. His special interest lies in the fields of advanced immunomodulation and biological therapy. He is a recognized authority on the use of infliximab (Remicade®) in Canada and co-authored the guidelines on the use of infliximab for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn's disease and ulcerative colitis.

He is presently the medical director for the Crohn's and Colitis Foundation Calgary Chapter and sits on the Medical Advisory council for the Crohn's and Colitis Foundation of Canada.

## Dr. Bruce Runyon



Dr. Bruce Runyon is a Clinical Professor of Medicine within the Division of Digestive Diseases and Director of Hepatology at UCLA/Santa Monica Medical Center. He completed his undergraduate training, medical school, externship in pathology, internal medicine residency and gastroenterology fellowship at the University of Iowa.

He was on the faculty of the University of Southern California at its 86-bed Liver Unit for eight years, including four years as chief. He also spent a decade in liver transplantation.

He was the first Hepatologist to be asked to write a US national practice guideline by the American Association for the Study of Liver Diseases. He has authored all four iterations of this guideline and is the last author of a single-authored American Association for the Study of Liver Diseases guideline.

He has been an author of multiple UpToDate topics on ascites and hepatoarenal syndrome since 1996 and has been the Editor for Complications of Cirrhosis at UpToDate since 2006. He was one of 24 US Hepatologists to lecture at the first American Association for the Study of Liver Diseases course for the Certificate of Advanced Qualification in Transplant Hepatology.

## Dr. Mark Swain



Dr. Mark Swain is currently a Professor of Medicine, Head of the Division of Gastroenterology, Hepatologist and Clinician-Scientist at the University of Calgary in Canada. He graduated from an MD-MSc (Pharmacology) combined program at Queen's University in Kingston. He completed his Internal Medicine training at the University of Toronto and his Gastroenterology training at McMaster University in Hamilton. He then undertook additional training in Hepatology in the Liver Unit at the National Institutes of Health, Bethesda Maryland. Dr. Swain has

basic bench research programs in two main areas, namely: i) Mechanisms underlying the development of fatigue in liver disease, and ii) the innate immune response in the regulation of hepatic inflammation. Dr. Swain's clinical research is focused in the areas of viral hepatitis and autoimmune liver disease. Dr. Swain has published numerous peer-reviewed papers and book chapters and has served on the Editorial Boards for the scientific journals Gut, American Journal of Physiology and Clinical Sciences. He has won many awards for teaching and research, including the University of Calgary Watanabe Distinguished Achievement Award for Overall Excellence. He is currently the Cal Wenzel Family Foundation Chair in Hepatology, and the Head of the Translational Research Core for the Snyder Institute, at the University of Calgary.

## Dr. Connie Switzer

---

Dr. Connie Switzer is a Clinical Professor of Medicine at the University of Alberta and a Consultant Gastroenterologist at the Grey Nun's Hospital in Edmonton, Alberta. She is interested in all luminal gastroenterology with special expertise in IBD and Celiac disease. She is Chair of the Canadian Celiac Association's Professional Advisory Board. Dr. Switzer has a keen interest in adult education and is the Chair of the Canadian Association of Gastroenterology's Maintenance of Certification Committee. She is the Chair of the Royal College of Physicians and Surgeons of Canada Gastroenterology Examination Committee. Dr. Switzer received the Queen's Golden Jubilee Medal for her work with the Canadian Celiac Association and recently received the Canadian Association of Gastroenterology Education Excellence Award. Dr. Switzer shares her life with her husband Alan and their children and grandchildren.

## Dr. Puneeta Tandon

---

Dr. Puneeta Tandon is a Hepatologist and Director of the Portal Hypertension Clinic at the University of Alberta Hospital in Edmonton. She completed her core Gastroenterology training at the University of Alberta. This was followed by a Master's in Clinical Epidemiology. Her subsequent Hepatology training was carried out at Yale University with Dr. Guadalupe Garcia-Tsao and at the Hospital Clinic in Barcelona, Spain with Dr. Jaime Bosch. Her clinical practice includes both pre and post transplant liver patients. Her research centers on body composition, functional changes and bacterial infections in patients with cirrhosis.

## Dr. Kenneth Wang

---



Dr. Kenneth Wang received his BS from the University of Michigan, Ann Arbor MI and his MD from Wayne State University, Detroit, Michigan. He completed his residency and fellowship at the Mayo Clinic, Rochester where he has remained on staff. Dr. Wang is the Kathy and Russ Van Cleave Professor of Gastroenterology Research

Dr. Wang is recognized for his expertise and research in the field of Barrett's esophagus and early esophageal cancer. He is director of Advanced Endoscopy, the Esophageal Neoplasia Clinic

and the Barrett's Esophagus Research Unit at Mayo Clinic Rochester. He has authored over 240 journal articles, book chapters and editorials related to Barrett's Esophagus and early esophageal cancer.

Dr. Wang built his research foundation on aspects of Barrett's Esophagus and early esophageal carcinomas. His work in the field has been recognized by his appointment on review panels for the National Institutes of Health, National Science Foundation and National Cancer Institute. Dr. Wang has served on multiple extramural committees for the NIH and NCI. He is currently President-elect for the American Society of Gastrointestinal Endoscopy. He is Associate Editor for the American Journal of Gastroenterology.

# SPONSORS

## Diamond Sponsors

abbvie



## Gold Sponsors



## Silver Sponsors



ALBERTA  
DIGESTIVE  
DISEASE  
SUMMIT

